For example, combined regimens of sorafenib or erlotinib with TGF-β inhibitor effectively potentiated sorafenib by increasing HCC cells apoptosis and suppressed the motility of erlotinib-resistant NSCLC cells, respectively (Serizawa et al., 2013; Serova et al., 2015). The gene discussed is TGFB1; the disease is hepatocellular carcinoma.